Lilly lays out sunny 2019 forecast driven by growth of new meds by Arlene Weintraub Wednesday, December 19, 2018 Lilly provided a forecast for next year that beat analysts’ expectations—welcome news as blockbuster Cialis faces generic rivals.
Lilly weighs $200M-plus sale of China drug portfolio: report by Arlene Weintraub Friday, November 16, 2018 Eli Lilly may have found one way to raise some quick cash to pour into its portfolio of growth prospects.
With Cialis under pressure, Lilly's new launches step up by Eric Sagonowsky Tuesday, November 6, 2018 Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.
Lousy basal insulin market prompts Merck to ditch Lantus biosim by Arlene Weintraub Friday, October 12, 2018 Merck canceled its partnership with Samsung Bioepis for a Lantus biosimilar after facing hurdles with pricing and production costs.
Lilly enlists new tech partner to improve outcomes in diabetes by Beth Snyder Bulik Monday, February 12, 2018 Eli Lilly and Livongo team up to tap real-world data to help diabetes patients adopt healthier habits and save money—and boost treatment results, too.
Lilly builds $23B sales forecast on diabetes, cancer launches by Eric Sagonowsky Wednesday, December 13, 2017 Eli Lilly is aiming for $23 billion in 2018 revenue, but it'll have to contend with a tough environment in diabetes and one hefty patent expiration.
Sanofi sues Mylan for Lantus patent infringement by Eric Sagonowsky Wednesday, October 25, 2017 Already under fire from one Lantus challenger, Sanofi is suing Mylan in an effort to hold off that company's version of its top-selling drug.
Merck scores FDA nod for Lantus copy Lusduna by Tracy Staton Thursday, July 20, 2017 Merck & Co. nabbed tentative FDA approval for its Lantus copy, Lusduna, which would be the second follow-on challenger to the Sanofi blockbuster.
